Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Calcifediol Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 8/20 | 0.82 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | SREBF1 | P36956 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.82 |
| ▸ | PGR | P06401 | 2/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
| ▸ | CDC25A | P30304 | 1/20 | 0.82 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.82 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.82 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.82 |
| ▸ | DRD3 | P35462 | 1/20 | 0.82 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcifediol Anhydrous SCHEMBL10018928 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL13301741 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL3296 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL24102681 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL5614025 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL24051907 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL14112503 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL24571935 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL22403256 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL12349027 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768804-B1 | 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES | WISCONSIN ALUMNI RES FOUND (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2768803-B1 | 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES | WISCONSIN ALUMNI RES FOUND (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2721004-B1 | 3-DESOXY-2-METHYLENE-19-NOR-VITAMIN D ANALOGS AND THEIR USES | WISCONSIN ALUMNI RES FOUND (US) | 2017-07-26 | — | — | EP | disclosed |
| US-8993547-B2 | 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2768804-A1 | 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES | Wisconsin Alumni Research Foundation (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2768803-A1 | 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES | Wisconsin Alumni Research Foundation (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8785422-B2 | A-ring modified 19-nor-vitamin D analogs and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-07-22 | — | — | US | disclosed |
| US-8729054-B2 | 3-desoxy-2-methylene-vitamin D analogs and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2721004-A1 | 3-DESOXY-2-METHYLENE-19-NOR-VITAMIN D ANALOGS AND THEIR USES | Wisconsin Alumni Research Foundation (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20130331459-A1 | A-Ring Modified 19-Nor-Vitamin D Analogs and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-12-12 | — | — | US | disclosed |
| US-8455467-B2 | 2-methylene-vitamin D analogs and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130102573-A1 | 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102567-A1 | 3-Desoxy-2-Methylene-Vitamin D Analogs and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013059021-A1 | 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20130102574-A1 | 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013059060-A1 | 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES | WISCONSON ALUMNI RESEARCH FOUNDATION (US) | 2013-04-25 | — | — | WO | disclosed |
| US-8410080-B1 | 2-methylene-vitamin D analogs and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120322775-A1 | 3-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012174095-A1 | 3-DESOXY-2-METHYLENE-19-NOR-VITAMIN D ANALOGS AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20120157418-A1 | 2-Methylene-19-Nor-Vitamin D Analogs and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102567-A1 | 3-Desoxy-2-Methylene-Vitamin D Analogs and Their Uses | VDR, CYP24A1, CYP2R1 | VDR 1/4885MAPT 3505/4885SMN1; SMN2 3677/4885 |
| US-20130102574-A1 | 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES | CYP24A1, VDR, CYP27B1 | VDR 2/4885MAPT 3959/4885SMN1; SMN2 3169/4885 |
| US-20130331459-A1 | A-Ring Modified 19-Nor-Vitamin D Analogs and Their Uses | VDR, CYP24A1, CYP2R1 | VDR 1/4885MAPT 4532/4885SMN1; SMN2 4498/4885 |
| US-20120157418-A1 | 2-Methylene-19-Nor-Vitamin D Analogs and Their Uses | CYP24A1, CYP2R1, CYP27B1 | VDR 4/4885MAPT 4259/4885SMN1; SMN2 2948/4885 |
| US-20130102573-A1 | 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES | VDR, CYP24A1, CYP2R1 | VDR 1/4885MAPT 3823/4885SMN1; SMN2 3219/4885 |
| US-20120322775-A1 | 3-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses | VDR, CYP24A1, CYP2R1 | VDR 1/4885MAPT 3557/4885SMN1; SMN2 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.